Reported Saturday, Senseonics Presents First Real-World Evidence Of Eversense 365 At ATTD, Showing 93.8% Adherence And Strong Glycemic Outcomes Across Full One-Year Wear

Benzinga Newsdesk www.benzinga.com Positive 95.2%

Neg 0% Neu 0% Pos 95.2%

Comments

No comments yet. Be the first!